Biotech, Securities Analysis Instructor
Delco worked in the life sciences industry for over twenty years and then as a Wall Street analyst and PM for over ten years. He was principal portfolio manager in Health at Weiss Peck & Greer/ROBECO where he achieved a 33% return in healthcare for 2005 and returned a composite performance of over 52% with his long/short portfolio.
While at Weiss Peck, as a consultant between 2005-2007 Delco founded a very important antibiotics biotech company (BioRelix) out of Dr. Ronald Breaker’s ground breaking riboswitch technology—recently closing a $25 million A round of financing with top VCs. He was also vice president and the senior biotech analyst at Natexis Bleichroeder where he led their biotech team. Prior to NB, Steven was with The Fortis Group as the senior biotech analyst and managing director where he created and managed a global biotech research team spanning Amsterdam, Paris and New York. In 1997, Delco started his Wall Street career at Miller Tabak + Co. LLC prior to founding a successful biotech newsletter that gained him notice on Wall Street. At MT, he built and headed the biotech research team. The Carson Group ranked him as the number one biotech analyst in 1999 due to stock picking performance that achieved a 294% return that year. Delco has also trained some of the leading analysts and portfolio managers on Wall Street.
Steven graduated from Fairfield University with a degree in biochemistry in 1974 and then completed doctoral graduate course work in immunochemistry and biochemistry at the University of Minnesota Delco's studies have cited in the Wall Street Journal, Bloomberg Online, and Reuters among others and was a contributor for Forbes Magazine. In addition, Steven has had teaching and research appointments at Sloan-Kettering Institute for Cancer Research, University of Minnesota, and City University of New York.
Healthcare, Securities finance and modeling instructor
Raúl Casado is a Finance lecturer at the HAN University of Applied Sciences in The Netherlands, where he covers a variety of areas: Financial Management, Investment Analysis, Financial and Managerial Accounting, Data Science, Business Intelligence and Data Analytics, among others; and he has trained university faculty overseas in valuation techniques for start-up ventures. Before his academic career, he worked in the Pharma/Biotech industry for two decades as a Financial Analyst.